AstraZeneca Pushes Into GI Cancers With HIMALAYA And TOPAZ-1

Not Quite At The Summit But Tremelimumab Hits A High

Pivotal data presented at the ASCO GI meeting in liver and biliary tract cancers could add a couple of billion dollars to Imfinzi’s sales and breathe new life into the CTL4 inhibitor tremelimumab.

AstraZeneca PLC could be looking at a multi-blockbuster opportunity for its immuno-oncology drug Imfinzi in gastrointestinal cancers on the back of full data from two Phase III studies presented this week at the ASCO GI meeting.

The company reported full data from the HIMALAYA study showing that its investigational CTLA-4 inhibitor tremelimumab may have a future...